Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
Globe Newswire1-08-2023, 19:23
Bridge International Academies highlights the importance of educating girls this World Population Day 11-07-2023, 09:00